Noonberg Sarah B.
Insider CIK 1706301 · MRNS Director · PTGX Director · NLTX Director · PRTA Chief Medical Officer · MGX Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NGNE Neurogene Inc. | A Award deriv | 2026-02-20 | 2026-02-24 | 12,050 | — | $0 | 12,050 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2025-06-12 | 2025-06-13 | 12,050 | — | $0 | 12,050 | SEC↗ |
| MGX Metagenomi, Inc. | S Sale | 2025-06-06 | 2025-06-09 | 5,239 | $1.75 | $9.2K | 109,135 | SEC↗ |
| MGX Metagenomi, Inc. | A Award deriv | 2025-04-01 | 2025-04-03 | 84,000 | — | $0 | 84,000 | SEC↗ |
| MGX Metagenomi, Inc. | A Award | 2025-04-01 | 2025-04-03 | 14,000 | — | $0 | 114,374 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award deriv | 2024-06-18 | 2024-06-20 | 10,450 | — | $0 | 10,450 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award | 2024-06-18 | 2024-06-20 | 2,300 | — | $0 | 14,100 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2024-06-14 | 2024-06-17 | 7,700 | — | $0 | 7,700 | SEC↗ |
| MGX Metagenomi, Inc. | A Award deriv | 2024-04-01 | 2024-04-03 | 242,875 | — | $0 | 242,875 | SEC↗ |
| MGX Metagenomi, Inc. | A Award | 2024-04-01 | 2024-04-03 | 57,763 | — | $0 | 100,374 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award deriv | 2024-01-18 | 2024-01-19 | 20,900 | — | $0 | 20,900 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award | 2024-01-18 | 2024-01-19 | 4,600 | — | $0 | 11,800 | SEC↗ |
| NGNE Neurogene Inc. | A Award deriv | 2024-01-16 | 2024-01-18 | 15,400 | — | $0 | 15,400 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2023-06-08 | 2023-06-09 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award deriv | 2023-05-16 | 2023-05-17 | 32,400 | — | $0 | 32,400 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS, I | A Award | 2023-05-16 | 2023-05-17 | 7,200 | — | $0 | 7,200 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2023-01-16 | 2023-01-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2022-05-26 | 2022-05-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2022-05-12 | 2022-05-16 | 25,000 | — | $0 | 25,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2021-05-27 | 2021-05-28 | 18,000 | — | $0 | 18,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2021-05-11 | 2021-05-13 | 25,000 | — | $0 | 25,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2021-02-11 | 2021-02-12 | 3,700 | — | $0 | 3,600 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2021-02-11 | 2021-02-12 | 3,700 | $25.09 | $92.8K | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2021-02-11 | 2021-02-12 | 3,700 | $6.98 | $25.8K | 3,700 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2021-02-10 | 2021-02-12 | 4,700 | — | $0 | 7,300 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2021-02-10 | 2021-02-12 | 4,300 | $25.42 | $109.3K | 400 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2021-02-10 | 2021-02-12 | 4,700 | $6.98 | $32.8K | 4,700 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2021-02-10 | 2021-02-12 | 400 | $26.04 | $10.4K | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2020-05-28 | 2020-05-29 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2020-05-05 | 2020-05-07 | 25,000 | — | $0 | 25,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2019-10-10 | 2019-10-15 | 22,000 | — | $0 | 22,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2019-06-07 | 2019-06-11 | 12,000 | — | $0 | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2018-05-29 | 2018-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2017-12-15 | 2018-03-15 | 24,000 | — | $0 | 24,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2017-12-15 | 2017-12-19 | 24,000 | — | $0 | 24,000 | SEC↗ |
| PRTA Prothena Corp plc | A Award deriv | 2017-05-16 | 2017-05-18 | 100,000 | — | $0 | 100,000 | SEC↗ |